IsoRay (ISR) stock: ready for another pop?

199
finstead.com/bite/IsoRay-ISR-stock-forecast-prediction-august-27-2018
IsoRay is a medical company that has developed Cesium-131 as a source for radiation therapy to combat various forms of cancer. In the case of prostate cancer, the company is reviving a procedure called prostate brachytherapy, which involves placing devices containing radiation in the prostate gland close to the cancer cells.

Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer but also in other forms of the disease. With a potential FDA approval, IsoRay has a chance to scale up; however, the company's current financial position is questionable. On July 10, IsoRay did a direct offering of 11 million common shares at $0.75 per share to institutional investors who also received warrants to purchase up to 5.5 million shares at $0.75.

إخلاء المسؤولية

لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.